Category Archives: Resistance to treatment

Editorial on Brain mets and ALK lung cancer

The Journal of Clinical Oncology has an editorial about the current research on treating brain mets for ALK+ patients that discusses ALK inhibitors and different kinds of radiation treatments. Treatments discussed include: 1) Crizotinib, 2) Ceritinib 3) Alectinib 4) brigatinib, … Continue reading

Posted in alectinib - Alecensa from Chugai - Roche - GenenTech, AP26113 - brigatinib from Ariad, Brain metastases, ceritinib - Zykadia from Novartis, crizotinib - Xalkori from Pfizer, Lung cancer, Potential Treatments, Research, Resistance to treatment, Side Effects | Leave a comment

Phase II results for Alectinib global study

Published November 23, 2015, Phase II trial results. Patients enrolled from June 2013 to April 2014. 122 evaluable patients who were all resistant to Crizotinib; overall objective response rate (ORR) of 50%. Disease Control Rate (DCR) was 79%. Median duration … Continue reading

Posted in alectinib - Alecensa from Chugai - Roche - GenenTech, Brain metastases, Lung cancer, Potential Treatments, Research, Resistance to treatment | Leave a comment

New ALK inhibitor reported

According to the article summary, current ALK inhibitors do not inhibit the G1202R mutant of the ALK gene, which is one of the most common mutations. The researchers announced the development of a structural analogue of Alectinib (called JH-VIII-157-02) that … Continue reading

Posted in Brain metastases, Glioblastomas, JH-VIII-157-02, Lung cancer, Neuroblastomas, Potential Treatments, Research, Resistance to treatment | Leave a comment

Comparison of 3 ALK inhibitors’ phase 2 trials

All of these results are based on 5 phase 2 trials. However the conditions of each trial may differ in important ways. For example, it is my understanding that the trial for brigatinib was limited to healthier patients while the … Continue reading

Posted in alectinib - Alecensa from Chugai - Roche - GenenTech, AP26113 - brigatinib from Ariad, Brain metastases, ceritinib - Zykadia from Novartis, Lung cancer, Potential Treatments, Research, Resistance to treatment | Leave a comment

3 Ceritinib abstracts

Abstracts 8060, 8059, and 8058 relate to Ceritinib. Please see glossary for acronym definitions. Abstract 8060 covers the Ascend 3 trial, which is a phase 2 trial that includes ALK inhibitor naive patients. As of 6-27-2014 the trial had 124 … Continue reading

Posted in Brain metastases, ceritinib - Zykadia from Novartis, Lung cancer, Potential Treatments, Research, Resistance to treatment | Leave a comment

2 abstracts on Crizotinib

Please see glossary for definitions of acronyms. Abstract 19135 is a survival comparison study of 3 ways of detecting the ALK fusion gene. This study was done in China and involved 75 (and possibly 98 patients). The abstract refers to … Continue reading

Posted in crizotinib - Xalkori from Pfizer, Lung cancer, Potential Treatments, Research, Resistance to treatment | Leave a comment

Potential mechanisms of resistance to ALK inhibitors

The Broad Institute did research on various types of resistance that can form to ALK inhibitors and published the results in Cell. “Understanding of the mechanisms leading to drug resistance is essential for the design of therapeutic strategies to improve … Continue reading

Posted in Lung cancer, Research, Resistance to treatment | Leave a comment

Effectivness of certain 2nd generation ALK inhibitors against specific ALK mutations

Four 2nd generation ALK inhibitors (Ceritinib, Alectinib, AP26113, and ASP3026) were tested in vitro against six known mutations of the ALK fusion gene. Generally, AP26113 (brigatinib) was most effective and ASP3026 was least effective. In some cases one drug worked … Continue reading

Posted in alectinib - Alecensa from Chugai - Roche - GenenTech, AP26113 - brigatinib from Ariad, ASP3026 from Astellas, ceritinib - Zykadia from Novartis, Lung cancer, Research, Resistance to treatment | Leave a comment

Video on Alectinib

Here is a video discussing Alectinib and comparing it with Crizotinib and Ceritinib. He also mentioned an upcoming trial that is being planned that would compare various sequences of the drugs. http://www.onclive.com/conference-coverage/thoracic-2014/Dr-Govindan-on-the-Potential-for-Alectinib

Posted in alectinib - Alecensa from Chugai - Roche - GenenTech, Brain metastases, ceritinib - Zykadia from Novartis, crizotinib - Xalkori from Pfizer, Research, Resistance to treatment | Leave a comment

ap26113 resistance in lymphoma

Several NPM-ALK resistant mutatations were identified in the lab. They provide targets for future research. http://www.ncbi.nlm.nih.gov/pubmed/25421750

Posted in Anaplastic Large-Cell Lymphomas, AP26113 - brigatinib from Ariad, Research, Resistance to treatment | Leave a comment